Loading…
Makes single-use medical devices, including disposable endoscopes, resuscitators and diagnostic equipment.
Makes single-use medical devices, including disposable endoscopes, resuscitators and diagnostic equipment.
Sells disposable devices used once, so hospitals reorder steadily. In endoscopy it sells reusable monitors as equipment and the disposable scopes as the recurring item. Resuscitators are an older, steadier product line.
Moat: narrow (IP / patents, switching costs). Pioneer in single-use endoscopy, reducing cross-infection risk and hospital reprocessing costs.
Headquarters: Ballerup, Denmark · Founded: 1937 · Employees: 5,384
Size Ambu A/S (AMBU-B.CO) is a Denmark Health Care company (Medical Specialties) with a market value of $3.42B, the 26th largest of 59 Denmark companies the cockpit tracks. Shares closed at DKK 87.60 on 6 Nov 2026.
Performance Over six months the shares gained 40.4%, against +6.2% for the median peer and +8.8% for the Denmark market (cap-weighted) — 5th highest of 21 in its peer set.
Growth Revenue grew 4.7% over the last twelve months (peer median +6.2%); the operating margin is 11.3% (peer median 9.5%).
Valuation It trades at 28.1× forward earnings against a peer median of 26.3× (7th most expensive of 18).
Price implies For today's price to make sense, revenue must grow about 13% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 3.0 points above its cost of capital (6.1% WACC).
Next results Next results expected around 28 Jan 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | DKK 6.24B | DKK 6.04B | DKK 5.39B | DKK 4.78B | DKK 4.44B |
| Revenue growth | — | +12% | +13% | +7% | — |
| Gross profit | DKK 3.75B | DKK 3.38B | DKK 2.96B | DKK 2.49B | DKK 2.37B |
| EBITDA | DKK 1.10B | DKK 1.16B | DKK 1.01B | DKK 632M | DKK 374M |
| Net income | DKK 510M | DKK 609M | DKK 235M | DKK 168M | DKK 93.0M |
| Free cash flow | DKK 737M | DKK 674M | DKK 725M | DKK 447M | -DKK 63.0M |
| Capital expenditure | DKK 540M | DKK 384M | DKK 289M | DKK 326M | DKK 558M |
| Total debt | DKK 579M | DKK 547M | DKK 558M | DKK 584M | DKK 1.84B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Ambu A/S AMBU-B.CO | $3.42B | +40% | +5% | 11% | 28.1× | 12.6% |
| Boston Scientific BSX | $62.0B | -21% | +9% | 21% | 13.8× | 5.0% |
| Olympus 7733.T | $12.2B | +13% | +8% | 16% | 18.0× | -1.5% |
| Medtronic MDT | $130B | +35% | +10% | 20% | 16.9× | 8.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | AMBU-B.CO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +23.8% | +7.3% | 2nd highest of 21 |
| 6-month return | +40.4% | +6.2% | 5th highest of 21 |
| Distance from 52-week high | -12.0% | -30.9% | 6th highest of 21 |
| Revenue growth (TTM) | +4.7% | +6.2% | 9th lowest of 19 |
| Operating margin | 11.3% | 9.5% | 9th highest of 19 |
| Forward P/E | 28.1× | 26.3× | 7th most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | 12.6% | 11.1% | 8th most demanding of 17 |
| Growth delivered (Del g) | +11.1% | +8.0% | 5th highest of 17 |
| Hurdle (Req g minus delivered) | +1.5 pp | +0.2 pp | 8th most demanding of 17 |
| ROIC minus cost of capital | +3.0 pp | -2.1 pp | 4th highest of 18 |
| EV / EBITDA | 20.7× | 11.5× | 4th most expensive of 10 |
| Net debt / EBITDA | -0.1× | 1.1× | 4th least indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Ambu A/S AMBU-B.CO | Denmark | $3.42B | +40% | +5% | 11% | 28.1× | 12.6% | +11.1% |
| Lepu Medical Technology (Beijing) 300003.SZ | China | $3.42B | -12% | -1% | 13% | 26.3× | 9.6% | -4.2% |
| MGI Tech 688114.SS | China | $3.42B | +9% | +2% | -7% | n/a | 46.5% | -0.1% |
| Autobio Diagnostics 603658.SS | China | $3.41B | +19% | +3% | 25% | 20.6× | -0.3% | +7.2% |
| Ottobock SE & Co. KGaA OBCK.DE | Germany | $3.36B | -25% | +5% | 15% | 15.4× | 3.5% | +8.0% |
| Carl Zeiss Meditec AFX.DE | Germany | $3.51B | +40% | 0% | 8% | 26.8× | 13.7% | +10.8% |
| Zhende Medical 603301.SS | China | $3.33B | -8% | +8% | 7% | 43.5× | 23.2% | -16.1% |
| iRay Technology 688301.SS | China | $3.54B | -8% | +58% | 24% | 27.5× | n/a | n/a |
| Sumitomo Bakelite 4203.T | Japan | $3.31B | +15% | +15% | 13% | 14.9× | 6.8% | +8.9% |
| Celcuity CELC | United States | $3.27B | -49% | n/a | n/a | n/a | n/a | n/a |
| Andon Health 002432.SZ | China | $3.60B | -29% | -30% | -26% | 15.0× | -7.7% | -7.4% |
| Shandong Weigao Blood Purification Products 603014.SS | China | $3.63B | -3% | +4% | n/a | 20.4× | -1.2% | +8.1% |
| SCHOTT Pharma AG & Co. KGaA 1SXP.DE | Germany | $3.67B | +31% | +4% | 15% | 22.1× | 11.7% | +11.0% |
| Stevanato STVN | United States | $3.70B | -26% | +12% | 18% | 19.3× | 10.6% | +12.1% |
| TransMedics TMDX | United States | $3.06B | +30% | +26% | 12% | 48.5× | 35.6% | +88.2% |
| Pulse Biosciences PLSE | United States | $3.87B | +179% | n/a | -7,008% | n/a | n/a | n/a |
| Axogen AXGN | United States | $2.99B | +19% | +24% | -5% | 76.5× | 48.8% | +14.9% |
| AtriCure ATRC | United States | $2.98B | +123% | +14% | 3% | 220.7× | 55.7% | +20.9% |
| iRhythm IRTC | United States | $2.97B | -25% | +26% | 1% | 182.6× | n/a | n/a |
| Envista NVST | United States | $4.04B | +4% | +12% | 11% | 15.6× | 6.8% | +7.1% |
| Tecan TECN.SW | Switzerland | $4.05B | +91% | -4% | 1% | 40.1× | 46.9% | +3.8% |